1 velop live, attenuated HAV vaccines that can
be administered orally.
2 erest in developing small molecules that can
be administered orally.
3 t hydrolysed by endogenous proteases and may
be administered orally.
4 reatment with succimer, a lead chelator that
is administered orally.
5 , large volumes of enteric contrast material
are administered orally.
6 mg/kg), a glycogen phosphorylase inhibitor,
was administered orally.
7 ample, 2.0 umol [14,15]-13C2-retinyl acetate
was administered orally.
8 All drugs
were administered orally.
9 Both drug regimens
were administered orally.
10 diesel/biodiesel fuel blend (80:20 v/v, B20)
were administered orally.
11 Drugs
were administered orally.
12 potecan CNS penetration, 200 mg/kg gefitinib
was administered orally 1 hour before 4 mg/kg topotecan
13 Pioglitazone (30 mg/kg weight)
was administered orally 1.5 h before and 2 h after the i
14 rvival occurred when 2 x 10(6) corneal cells
were administered orally 10 days before orthotopic corne
15 Ivosidenib
was administered orally (
100 mg twice daily to 1,200 mg
16 Two days later, 400 mg of ketoconazole
was administered orally 2 hr before to the morning dose.
17 Biotin
was administered orally (
2.1, 8.2, or 81.9 micromol) or
18 Acalabrutinib
was administered orally 200 mg once daily, or 100 mg twi
19 pression of the NGF receptor-IR elements, C3
was administered orally (
25 mg/kg, once a day), by gavag
20 or myelodysplastic syndromes (MDS), MGCD0103
was administered orally 3 times weekly without interrupt
21 TMZ
was administered orally 30 minutes after completion of e
22 eased in diabetic subjects only when glucose
was administered orally (
37.8 +/- 14.9 vs 68.3 +/- 22.8
23 Treatment
was administered orally 5 d/wk for 3 months.
24 PN401
was administered orally 8 hours after 5-FU administratio
25 Acyclovir or a matched placebo
was administered orally,
800 mg five times daily, for 21
26 Treatments
were administered orally,
801 mg or 399 mg three times a
27 A-988315 (20 or 60 mg/kg) or water
was administered orally 90 min before retention testing,
28 lective high-affinity FXR inhibitor that can
be administered orally and prevents, or reverses, high-f
29 principal adverse event observed when 2-CdA
was administered orally and IV.
30 Peanut or placebo (oat) flour
was administered orally and participants and the study t
31 Contrast media
were administered orally and by means of an enema.
32 All drugs
were administered orally and doses varied by drug combin
33 Zinc stable isotopes
were administered orally and intravenously.
34 All interventions
were administered orally and were given for 3 months aft
35 d murine lymphoid tumors (even when the drug
was administered orally)
and against human breast and bl
36 (13)C-glycerol tripalmitin
was administered orally as an independent measure of CM
37 VP-16
was administered orally as repeated 21-day courses at 50
38 oscine (21 mg/kg), and ondansetron (5 mg/kg)
were administered orally as positive controls (PCs).
39 in fixed-dose combination pills; other drugs
were administered orally as separate pills.
40 Immunosuppressants
were administered orally as single daily doses.
41 RAD
was administered orally at 0.5 mg/kg per day for days 0
42 Everolimus
was administered orally at 10 mg daily and letrozole was
43 Zanubrutinib
was administered orally at 160 mg twice per day (28-day
44 nistered orally at 10 mg daily and letrozole
was administered orally at 2.5 mg daily.
45 During dose escalation, ivosidenib
was administered orally at 200-1200 mg daily in 28-day c
46 Terbutaline (0.2-0.3 mg/kg)
was administered orally at 24 and 36 h.
47 Lenalidomide
was administered orally at 25 mg on days 1 through 21 of
48 Marimastat
was administered orally at 25, 50, or 100 mg twice daily
49 Adavosertib
was administered orally at 300 mg once daily on days 1-5
50 Sorafenib
was administered orally at 400 mg twice daily on a conti
51 Ruxolitinib
was administered orally at 5 mg twice daily for children
52 Alisertib
was administered orally at 50 mg twice daily for 7 days
53 During a 24-week core period, mitapivat
was administered orally at 50 mg twice daily for the fir
54 Prednisone or a matched placebo
was administered orally at 60 mg/d for the first 7 days,
55 Everolimus
was administered orally at a daily dose of 2.1, 3, 5, or
56 Lenalidomide
was administered orally at a dose of 25 mg on days 1 to
57 Ibrutinib
was administered orally at a dose of 560 and 420 mg once
58 Lenvatinib
was administered orally at a starting dose of 11 mg/m(2)
59 In nonclinical studies, fidaxomicin
was administered orally at approximately 1 g/kg/d to dog
60 ither human or nonhuman primate populations,
was administered orally at doses ranging from 10(6) to 1
61 Drug
was administered orally at escalating doses as a solutio
62 Quizartinib
was administered orally at escalating doses of 12 to 450
63 VXA-G1.1-NN
was administered orally at three dose levels by prime an
64 PT2385
was administered orally at twice-per-day doses of 100 to
65 3C, methyl-2H3]methionine and [2H2]cysteine)
were administered orally at 30-min intervals for 8 h.
66 rated virulence attenuation when the strains
were administered orally but not when they were administ
67 In groups PROB and LIP/PROB, the PROB
was administered orally by addition to the drinking wate
68 Larotrectinib
was administered orally (
capsule or liquid formulation),
69 y, the intravenous formulation of irinotecan
was administered orally daily for 5 days for 2 consecuti
70 Temozolomide
was administered orally daily for 5 days, with subsequen
71 Ivosidenib
was administered orally daily in 28-day cycles.
72 Vorinostat
was administered orally daily starting at 180 mg/m(2)/d
73 Erlotinib
was administered orally daily to groups of at least thre
74 mg/kg), a glycogen phosphorylase inhibitor,
was administered orally,
either alone to create mild hyp
75 Thereafter, 80 mg/kg hydroxyurea
was administered orally every 3 days.
76 methionine aminopeptidase type 2 inhibitor,
was administered orally every other day at 1, 5, or 10 m
77 Pravastatin and nicotinamide
were administered orally every day for 14 days, starting
78 tive antiviral against SARS-CoV-2 that could
be administered orally for use following high-risk expos
79 Venetoclax
was administered orally for 14 days each cycle.
80 Citicoline (500 mg/day)
was administered orally for 6 weeks, and patients were f
81 PSC 833
was administered orally for 7 days, beginning 72 hours b
82 AQX-1125 (450 mg daily) or placebo
was administered orally for 7 days.
83 In the present phase 1 study, capravirine
was administered orally for up to 28 days to 55 HIV-1-in
84 ice a day (DL1) and 200 mg twice a day (DL2)
was administered orally from days 1 to 5 and 8 to 12; al
85 ndothelial cells from relevant donor strains
were administered orally from day -14 to day -4 on a dai
86 hat any potential neuroprotective agent must
be administered orally,
have a safe profile and poses a
87 In addition, we propose that the vaccine
be administered orally in a 2-dose schedule, with the fi
88 Alisertib
was administered orally in 21-day cycles at the recommen
89 C3
was administered orally in 5, 10, and 25 mg/kg/day conce
90 th conventional antimicrobial therapy, which
was administered orally in 96 percent.
91 fashion via subcutaneous implant, whereas P
was administered orally in a cyclic fashion.
92 Colchicine
was administered orally in a loading dose of 1.5 mg imme
93 ronic disease, a range of doses (0.4-100 mg)
was administered orally in a single dose before challeng
94 MA 800 mg/d
was administered orally in divided doses.
95 Olutasidenib
was administered orally in doses of 150 mg once daily, 1
96 WAY-202196 or control (vehicle)
was administered orally in doses ranging from 1.5 to 50
97 SM16
was administered orally in formulated chow.
98 Dasatinib (15 to 240 mg per day)
was administered orally in four-week treatment cycles, o
99 ated escalations in the dose of PLX3397 that
was administered orally in patients with solid tumors (d
100 Nicotine
was administered orally in the drinking water to achieve
101 Olaparib
was administered orally in the form of tablets and given
102 Both treatments
were administered orally in 10 ml (increasing to 20 ml,
103 When suboptimal doses
were administered orally in combination to wild-type mic
104 The NRTI drugs allocated by randomisation
were administered orally in fixed-dose combination pills
105 (2.5 mug, 5.0 mug, or 10.0 mug), or placebo
were administered orally in two doses 2 weeks apart.
106 Arimoclomol
was administered orally,
in drinking water, from symptom
107 Both drugs
were administered orally,
in tablet formulation.
108 Oseltamivir (GS4104), which can
be administered orally,
is the prodrug of GS4071, a pote
109 ve a favorable risk-to-benefit ratio when it
is administered orally long-term to patients with the pr
110 dehydrogenase, allows fluorouracil (5-FU) to
be administered orally on a schedule that simulates cont
111 Palbociclib 125 mg/d
was administered orally on a 21-days-on, 7-days-off sche
112 Dexamethasone 40 mg daily
was administered orally on days 1, 8, 15, and 22 of each
113 Therapy
was administered orally on the first 5 days of a 28-day
114 xamethasone (20 mg [10 mg if age >75 years])
was administered orally on the same days as bortezomib a
115 Both drugs
were administered orally on a 3 weeks 'on' and 1 week 'o
116 Melphalan and prednisone
were administered orally on days 1 to 4; carfilzomib was
117 Temodar
was administered orally once a day for five consecutive
118 Pirtobrutinib 200 mg
was administered orally once a day in 28-day cycles.
119 COL-3
was administered orally once daily at one of two doses (
120 Ribociclib
was administered orally once daily for 16 days after TOT
121 Darapladib 160 mg or placebo monotherapy
was administered orally once daily for 3 months, and pat
122 Sunitinib (25, 37.5, or 50 mg)
was administered orally once daily on three dosing sched
123 Erlotinib
was administered orally once daily to cohorts of three t
124 COL-3
was administered orally once daily, and doses were escal
125 Pazopanib 800 mg
was administered orally once daily.
126 LCL161
was administered orally,
once weekly, on a 21-day cycle
127 uires weeks of antibiotic therapy, which can
be administered orally or intravenously via a peripheral
128 in that makes use of a unique mechanism, can
be administered orally or subcutaneously.
129 solution of diatrizoate meglumine and sodium
was administered orally or by means of a nasogastric tub
130 Sertraline
was administered orally or via nasogastric tube at a dos
131 shown that this novel formulation of AmB can
be administered orally,
resulting in 99% inhibition of p
132 ificant number (N = 34) of these macrocycles
are administered orally,
revealing that oral bioavailabi
133 Both treatments
were administered orally starting at 1.0 mg three times
134 All drug doses
were administered orally:
sunitinib 50 mg, 4 weeks on an
135 Dipyridamole 75 mg
was administered orally three times daily during the FU
136 dose-escalation phase (n = 47), panobinostat
was administered orally thrice weekly every week in comb
137 ntrate derived from pooled donor breast milk
was administered orally to 32 healthy adults for 7 days
138 STI571
was administered orally to 83 patients with CML in the c
139 9-cis-Retinal
was administered orally to a subset of Rpe65(-/-) mice,
140 PT150 (900 mg/day)
was administered orally to all participants for five day
141 Gefitinib (150, 300, 400, or 500 mg/m2)
was administered orally to cohorts of three to six patie
142 mg/kg), a glycogen phosphorylase inhibitor,
was administered orally to decrease glucose output in ea
143 eptide synthesized from D-amino acids (D-4F)
was administered orally to LDL receptor-null mice on a W
144 Then, to assess its efficacy in vivo, BTKB66
was administered orally to mice for 7 days before subjec
145 ARRY-063
was administered orally to ovalbumin (OVA) sensitized an
146 Lorlatinib
was administered orally to patients at doses ranging fro
147 lective P2X3 and P2X2/3 receptor antagonist,
was administered orally to rats and found to produce hig
148 lead that also contained two chlorine atoms
was administered orally to rats, and samples of bile, ur
149 lbladder filling, 30 mL of corn oil emulsion
were administered orally to all patients followed by dyn
150 Vector strains
were administered orally to germfree mice that were subs
151 ailability was established whereby compounds
were administered orally to mice and plasma levels were
152 The compounds
were administered orally to mice with acute T. cruzi inf
153 Antigens
were administered orally to mice, and antigen-specific g
154 asing doses of egg white or ovomucoid as OIT
were administered orally to sensitized mice.
155 Elacridar and cold erlotinib
were administered orally to wild-type (WT) and Abcb1a/b;
156 d once a day on days 1 to 28 and abexinostat
was administered orally twice a day on days 1 to 5, 8 to
157 Patients and Methods MK-8242
was administered orally twice a day on days 1 to 7 in 21
158 During dose escalation, rogaratinib
was administered orally twice daily at 50-800 mg in cont
159 Lonafarnib
was administered orally twice daily at dose levels of 70
160 Lapatinib
was administered orally twice daily at escalating doses
161 Capecitabine (825, 1,000, or 1,250 mg/m(2))
was administered orally twice daily on days 1 to 14 ever
162 both study groups, 5.0 mg/kg of cyclosporine
was administered orally twice daily starting 3 days befo
163 s phase 2 open-label study, 400 mg nilotinib
was administered orally twice daily to 280 patients with
164 ML120B
was administered orally twice daily, either prophylactic
165 AZD1775
was administered orally twice per day over 2.5 days per
166 ct (active) and appropriate placebo solution
were administered orally twice daily for 12 months, and
167 (acetylcysteine 1200 mg or matching placebo)
were administered orally twice daily for 2 doses before
168 NALL or matching placebo
was administered orally two to three times per day, with
169 Ibrutinib at a daily dose of 420 mg
was administered orally until disease progression or the
170 Belzutifan
was administered orally using a 3 + 3 dose-escalation de
171 Allogeneic dendritic cells (DC)
were administered orally using a protocol that is known
172 A taste-masked preparation of SNAC 2.25 g
was administered orally with heparin 30000 to 150000 IU.
173 70Zn and dysprosium
were administered orally with all meals for 5 consecutiv
174 Axitinib or placebo
were administered orally with food at a starting dose of
175 Temozolomide
was administered orally within 60 minutes of the end of